X
[{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$160.0 million","upfrontCash":"Undisclosed","newsHeadline":"Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Hoag","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Hoag Enrolling Patients for Clinical Trial of Promising New Investigational Treatment for Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acumen Publishes Phase 1 Trial Design and Clinical Development Plan for ACU193, an Anti-Amyloid Beta Oligomer Antibody for Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic A\u03b2 Oligomers in Patients with Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"BofA Securities","pharmaFlowCategory":"D","amount":"$130.0 million","upfrontCash":"Undisclosed","newsHeadline":"Acumen Announces Pricing of Upsized $130 Million Public Offering","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"July 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Halozyme Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of ACU193 with ENHANZE\u00ae Technology","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"K2 HealthVentures","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2023","url1":"","url2":"","graph1":"Neurology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Lonza Group","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Acumen Pharmaceuticals Collaborates with Lonza to Advance Sabirnetug for the Treatment of Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"April 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer's Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"},{"orgOrder":0,"company":"Acumen Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Acumen Pharmaceuticals Announces First Patient Dosed in ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer\u2019s Disease","therapeuticArea":"Neurology","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Neurology","graph2":"Phase III"}]
Find Clinical Drug Pipeline Developments & Deals by Acumen Pharmaceuticals
Filters
Companies By Therapeutic Area
Details:
ACU193 (sabirnetug) is a humanized monoclonal antibody (mAb), it selectively targets toxic soluble AβOs which is the primary underlying cause of the neurodegenerative process in alzheimer’s disease.
Lead Product(s):
Sabirnetug
Therapeutic Area: Neurology
Product Name: ACU193
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 08, 2024
Details:
ACU193 (sabirnetug) is a humanized monoclonal antibody that targets toxic soluble amyloid beta oligomers. It is being evaluated for the treatment of early alzheimer’s disease.
Lead Product(s):
Sabirnetug
Therapeutic Area: Neurology
Product Name: ACU193
Highest Development Status: Phase III
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
May 08, 2024
Details:
Lonza will manufacture the ACU193 (sabirnetug) drug substance, the first monoclonal antibody candidate to enter the clinic developed to selectively target toxic soluble amyloid beta oligomers, which evidence indicates are a primary underlying cause of Alzheimer’s disease.
Lead Product(s):
Sabirnetug
Therapeutic Area: Neurology
Product Name: ACU193
Highest Development Status: Phase III
Product Type: Large molecule
Recipient:
Lonza Group
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
April 04, 2024
Details:
The proceends will be used to support development of a subcutaneous formulation of ACU193, a humanized monoclonal antibody that selectively targets toxic soluble amyloid beta oligomers.
Lead Product(s):
ACU193
Therapeutic Area: Neurology
Product Name: ACU193
Highest Development Status: Phase I/ Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
K2 HealthVentures
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Financing
November 13, 2023
Details:
The collaboration will provide Acumen access to Halozyme's ENHANZE® drug delivery technology, based on a recombinant human hyaluronidase PH20 enzyme (rHuPH20), for the development of a subcutaneous formulation of ACU193, the first clinical-stage AβO-targeting antibody.
Lead Product(s):
ACU193
Therapeutic Area: Neurology
Product Name: ACU193
Highest Development Status: Phase I/ Phase II
Product Type: Large molecule
Recipient:
Halozyme Therapeutics
Deal Size: Undisclosed
Upfront Cash: Undisclosed
Deal Type: Collaboration
November 06, 2023
Details:
Acumen intends to use its net proceeds to fund the Phase 2 portion of a future, potential Phase 2/3 adaptable trial of ACU193, an anti-AβO mAb developed to selectively target and inhibit toxic soluble AβOs, to fund chemistry, manufacturing and other R&D activities.
Lead Product(s):
ACU193
Therapeutic Area: Neurology
Product Name: ACU193
Highest Development Status: Phase I/ Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
BofA Securities
Deal Size: $130.0 million
Upfront Cash: Undisclosed
Deal Type: Public Offering
July 18, 2023
Details:
Acumen intends to use its net proceeds to fund the Phase 2 portion of a future, potential Phase 2/3 adaptable trial of ACU193, an anti-AβO mAb developed to selectively target and inhibit toxic soluble AβOs, to fund chemistry, manufacturing and other R&D activities.
Lead Product(s):
ACU193
Therapeutic Area: Neurology
Product Name: ACU193
Highest Development Status: Phase I/ Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
BofA Securities
Deal Size: $100.0 million
Upfront Cash: Undisclosed
Deal Type: Public Offering
July 17, 2023
Details:
ACU193 is a humanized monoclonal antibody (mAb), it selectively targets toxic soluble AβOs whic is the primary underlying cause of the neurodegenerative process in alzheimer’s disease.
Lead Product(s):
ACU193
Therapeutic Area: Neurology
Product Name: ACU193
Highest Development Status: Phase I/ Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 13, 2023
Details:
ACU193 is a humanized monoclonal antibody discovered and developed based on its selectivity for soluble AβOs, which scientific evidence indicates are the most toxic and pathogenic form of Aβ, relative to Aβ monomers and amyloid plaques.
Lead Product(s):
ACU193
Therapeutic Area: Neurology
Product Name: ACU193
Highest Development Status: Phase I/ Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 01, 2022
Details:
ACU193 targets amyloid-beta oligomers and is a different approach to treating Alzheimer's disease than currently approved medications. ACU193 is designed to locate and bind to amyloid-beta oligomers – proteins that build up in the brain.
Lead Product(s):
ACU193
Therapeutic Area: Neurology
Product Name: ACU193
Highest Development Status: Phase I/ Phase II
Product Type: Large molecule
Partner/Sponsor/Collaborator:
Hoag
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 20, 2022